EU Compliance Posture.

1. REACH (Regulation (EC) No 1907/2006)

REACH requires registration of substances manufactured in or imported into the EU/EEA at or above one tonne (1000 kg) per legal entity per year, in accordance with Article 6 of the Regulation. Research-grade peptides supplied as lyophilised powder in milligram-scale vials sit far below this threshold for our combined catalogue and per-substance flow.

Current posture: TogoPeptide is below the REACH registration threshold on a per-substance basis. We monitor cumulative annual flow per compound; should any single compound approach the one-tonne threshold we will (a) pause sales of that compound, (b) commission a Lead Registrant filing or join an existing SIEF, and (c) update this page with the registration number before re-opening sales.

Substances supplied exclusively for product- and process-orientated research and development (PPORD) may benefit from the time-limited PPORD exemption under Article 9, but we do not currently rely on PPORD because our volumes do not require registration in the first place.

2. CLP (Regulation (EC) No 1272/2008)

CLP harmonises the classification, labelling and packaging of substances and mixtures placed on the EU market. CLP applies regardless of tonnage. Our compounds are supplied as lyophilised research peptides, not as bulk industrial chemicals or consumer mixtures. The vast majority of catalogue items are not assigned a harmonised CLP classification under Annex VI.

Current posture: each shipment leaves with batch-specific identification (compound name, sequence reference, batch ID, mass) on the vial. Where a Safety Data Sheet (SDS) is required by Article 31 REACH for a specific compound we provide one on request to verified institutional buyers. For laboratory-scale research peptides not classified as hazardous under CLP an SDS is generally not mandatory but we will furnish one in good faith if a research institution's procurement workflow requires it.

3. EU dual-use export controls

Regulation (EU) 2021/821 governs the export, brokering, transit, transfer and technical assistance for dual-use items. Annex I lists controlled items. The peptide compounds in our catalogue do not appear on the dual-use list and are not export-controlled under this regime.

Independent of dual-use scoping, we comply with EU restrictive measures (sanctions) and US OFAC restrictions on a destination basis — see the Shipping Restrictions page for the country list with source citations.

4. Aspirational items (clearly marked)

The following are forward-looking and not in place today:

• Voluntary publication of an SDS for the top 10 catalogue compounds.
• Annual third-party review of cumulative tonnage per compound (currently performed in-house from order-management data).
• Formal CLP self-classification dossier per compound, archived alongside the per-batch COA.

We will update this page when an aspirational item moves into production. Do not infer the existence of these controls from this page alone.

5. Contact

Compliance questions: compliance@togopeptide.com. For our legal identity, postal address and chamber-of-commerce reference see the Imprint. This page complements the Terms & Conditions and the Privacy Policy.

Last reviewed: 2026-05-09. This statement is reviewed at least annually and on any material change to scope or threshold.